Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #27902 on Imaging Diagnostic Systems (fka IMDS)
jmurfk
09/17/12 12:53 PM
#27905 RE: Cool_Trades #27902
There will never be an R/S, all anyone has to do is call the company and talk to Linda Grable
Only a matter of time when this round of dilution is over that the company announces their financing, which will be of the non-toxic long term type as stipulated in their 10Q.
stockmasterflash
09/17/12 12:54 PM
#27906 RE: Cool_Trades #27902
09/17/12 1:12 PM
#27911 RE: Cool_Trades #27902
In case anyone didn't know, IMDS was former NASDAQ trading above $6/share in 2000 before the ex-CEO's death.
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS The Company's common stock, no par value, is traded on the over-the-counter bulletin board market. The Company's preferred stock is not traded. There has been trading in the Company's common stock since September 20, 1994. The symbol for the Company's common stock is IMDS.
NASDAQ LISTING On July 21, 1999, we received an opinion of the U.S. Securities and Exchange Commission (the "Commission") dismissing our application for review of our appeal to the denial of our application for Nasdaq Small Cap Market listing. The Commission found that Nasdaq did not exceed its authority by requiring us to (i) satisfy the $4.00 per share bid price requirement; (ii) satisfy all other requirements for initial listing; and (iii) evidence a minimum of $5,000,000 in net tangible assets. The Commission went on to say that the specific grounds identified as the basis for Nasdaq imposing the conditions for inclusion (i.e. the our stock price was well below the $4.00 minimum required for Nasdaq inclusion and concern that we would not be able to maintain compliance with the $2,000,000 net tangible assets maintenance requirement over the long term) existed in fact and therefore Nasdaq did not exceed its authority by requiring the net tangible assets and share bid price conditions. We do not intend to take any further action in this matter.